Sight Sciences carries a genuine earnings-beat catalyst, but a Rule-of-40 failure, sustained insider selling, and an already-reached valuation target with negative near-term asymmetry keep the setup unfavorable.
Thesis pillars
- Earnings Beat Streak→Stable
- Rule Of 40 Failure→Stable
- Insider Selling Pressure→Stable
- +1 more pillar — see the Why tab for full reasoning
Sight Sciences, Inc. (SGHT) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $8.35: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum.
Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and SION for MIGS procedures) and Interventional Dry Eye (TearCare for meibomian gland disease). The company estimates addressable U.S. markets of about $6.0 billion... Read more
Sell if holding. Engine safety override at $8.35: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Sight Sciences, Inc.
About Sight Sciences, Inc.
Sight Sciences sells three FDA-cleared interventional ophthalmology devices — OMNI and SION for microinvasive glaucoma surgery, and TearCare for meibomian gland disease — with OMNI expected to remain the majority of revenue over the next twelve months. The company operates direct commercial teams in the United States, United Kingdom, and Germany, selling into other European markets through distributors. Sight Sciences reported a $38.4 million net loss in 2025 against a $384.7 million accumulated deficit.
Sight Sciences generates revenue from OMNI and SION sales to ophthalmic surgeons, ambulatory surgery centers, and hospital outpatient departments performing MIGS procedures, billed to Medicare, Medicaid, and commercial payors under Category I CPT codes 66174 (canaloplasty) and 65820 (goniotomy), while TearCare is billed under the newer Category III CPT code 0563T, for which reimbursement remains uneven across Medicare Administrative Contractors and commercial plans. The company's more than 100-person commercial team focuses on physician training and clinical education to drive adoption, supported by a growing base of peer-reviewed publications — 34 articles on OMNI since 2018 alone. Manufacturing is outsourced to third-party manufacturers rather than produced in-house. Looking forward, Sight Sciences is running early-stage trials for a next-generation Helix Surgical System and an OMNI 3.0 device, both first-in-human studies registered in 2025.
Show full overview
Payer policy has already moved OMNI's economics in a measurable way: CMS cut the Medicare Physician Fee Schedule payment tied to CPT code 66174 (the canaloplasty code most OMNI procedures bill under) from approximately $950 in 2021 to $545 in 2026, a decline the company says has made the code less attractive to providers. Separately, in 2023 five of seven Medicare Administrative Contractors proposed local coverage determinations classifying OMNI's canaloplasty-trabeculotomy procedure as investigational; though withdrawn, the replacement policies still bar coverage when a MIGS procedure combines with an aqueous shunt or stent, a restriction the company says has already reduced MIGS claims volumes.
See also: Healthcare · Medical Devices
From Sight Sciences, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-09-06Recent Developments — Sight Sciences, Inc.
Latest news
- NEWS Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18 — benzinga Aug 19, 2026 positive
Generated 2026-09-06T19:26:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductOMNI10-K Item 1A: 'We believe that OMNI sales will continue to account for the majority of our revenue over the next twelve months.'
Material Events(8-K, last 90d)
- 2026-08-10Item 5.02LOWSight Sciences appointed Kashif Rashid (ex-Nevro Corp GC) as Chief Legal Officer and Corporate Secretary, effective August 10, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -35.7%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.35: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $7.77. Score 4.8/10, moderate confidence.
Take-profit target: $8.67 (-6.2% upside). Prior stop was $7.77. Stop-loss: $7.77.
Target reached (-6.2% upside); Quality below floor (3.4 < 4.0).
Sight Sciences, Inc. trades at a P/E of N/A (forward -19.3). TrendMatrix value score: 5.0/10. Verdict: Sell.
14 analysts cover SGHT with a consensus score of 4.0/5. Average price target: $9.
What does Sight Sciences, Inc. do?Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and...
Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and SION for MIGS procedures) and Interventional Dry Eye (TearCare for meibomian gland disease). The company estimates addressable U.S. markets of about $6.0 billion for glaucoma and $2.4 billion for dry eye, selling mainly through a direct U.S. sales team, with OMNI expected to remain the majority of near-term revenue.